Unknown

Dataset Information

0

A pilot study of weekly brentuximab vedotin in patients with CD30+ malignancies resistant to brentuximab vedotin every 3 weeks.

ABSTRACT:

SUBMITTER: Poston JN 

PROVIDER: S-EPMC6589112 | biostudies-literature | 2019 Jul

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

A pilot study of weekly brentuximab vedotin in patients with CD30+ malignancies resistant to brentuximab vedotin every 3 weeks.

Poston Jacqueline N JN   Fromm Jonathan R JR   Rasmussen Heather A HA   Shustov Andrei R AR   Libby Edward N EN   Smith Stephen D SD   Gooley Ted T   Gopal Ajay K AK  

British journal of haematology 20181228 1

Similar Datasets

Unknown Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies.
| S-EPMC3994656 | biostudies-literature
Unknown Population Pharmacokinetics of Brentuximab Vedotin in Patients With CD30-Expressing Hematologic Malignancies.
| S-EPMC5574006 | biostudies-literature
Unknown Brentuximab vedotin does not cause clinically relevant QTc interval prolongation in patients with CD30-positive hematologic malignancies.
| S-EPMC3932653 | biostudies-literature
Unknown Brentuximab vedotin, an antibody-drug conjugate, in patients with CD30-positive haematologic malignancies and hepatic or renal impairment.
| S-EPMC5089583 | biostudies-literature
Unknown Retreatment with Brentuximab Vedotin in Patients with Relapsed/Refractory CD30+ Malignancies: A Retrospective Medical Chart Review Study in Spain-The BELIEVE Study.
| S-EPMC11987772 | biostudies-literature
Unknown A phase 2 study of brentuximab vedotin in patients with CD30-positive advanced systemic mastocytosis.
| S-EPMC6693006 | biostudies-literature
Unknown CYP3A-mediated drug-drug interaction potential and excretion of brentuximab vedotin, an antibody-drug conjugate, in patients with CD30-positive hematologic malignancies.
| S-EPMC3777854 | biostudies-literature
Unknown Targeting CD30 Using Brentuximab Vedotin in the Treatment of Hodgkin Lymphoma.
| S-EPMC5042201 | biostudies-literature
Unknown Response to Brentuximab Vedotin by CD30 Expression in Non-Hodgkin Lymphoma.
| S-EPMC9526494 | biostudies-literature
Unknown Randomized Phase II Study of Brentuximab-Vedotin With High-Dose Chemotherapy in CD30 Positive Lymphoma.
| S-EPMC12539077 | biostudies-literature